The investigation of antimicrobial peptides expression and its related interaction with methotrexate treatment in patients with psoriasis vulgaris

Basit Öğe Kaydı
dc.contributor.authorOzlu, Emin
dc.contributor.authorKaradag, Ayse Serap
dc.contributor.authorOzkanli, Seyma
dc.contributor.authorOguztuzun, Serpil
dc.contributor.authorAkbulak, Ozge
dc.contributor.authorUzuncakmak, Tugba Kevser
dc.contributor.authorAkdeniz, Necmettin
dc.date.accessioned2020-06-25T18:23:28Z
dc.date.available2020-06-25T18:23:28Z
dc.date.issued2017
dc.departmentKırıkkale Üniversitesi
dc.descriptionUzuncakmak, Tugba Kevser Ustunbas/0000-0001-8057-3463
dc.description.abstractBackground: Psoriasis is a chronic, inflammatory and immune-mediated disease. Recently, the role of antimicrobial peptides (AMPs) such as human beta defensins (hBDs) in the pathogenesis of psoriasis has been investigated. We aimed to evaluate the expression profiles of hBD-1 and hBD-2 in psoriatic skin before and after methotrexate (MTX) therapy and to compare healthy controls. Methods: Immunohistochemical expressions of hBD-1 and hBD-2 were assessed in 16 patients with psoriasis vulgaris and 20 normal skin biopsies from healthy controls. The patients were administered a 12 week of MTX and skin biopsy samples were obtained from the lesional skin of the patients pre-/posttreatment and normal body of the healthy controls. Results: The median (range) Psoriasis Area and Severity Index (PASI) value was 21.6 (8.2-27.7) before the treatment whereas; 3.05 (1-23.4) after the treatment. hBD-1 expression in psoriasis patients was significantly higher as compared to the healthy controls before treatment (p > 0.01). No significant difference was observed between psoriasis patients and healthy controls in terms of hBD-2 expression before treatment (p > 0.05). No significant difference was observed between before-after MTX treatment in terms of hBD-1 and hBD-2 expression levels in psoriasis patients (p > 0.05). Conclusions: These findings suggest a role for hBD-1 in psoriasis pathogenesis. But MTX treatment does not affect on hBD-1 and hBD-2 expressions. Further studies are needed to assess the roles of these AMPs in psoriasis etiopathogenesis.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1080/15569527.2016.1277430
dc.identifier.endpage326en_US
dc.identifier.issn1556-9527
dc.identifier.issn1556-9535
dc.identifier.issue4en_US
dc.identifier.pmid28067065
dc.identifier.scopus2-s2.0-85010639770
dc.identifier.scopusqualityQ3
dc.identifier.startpage321en_US
dc.identifier.urihttps://doi.org/10.1080/15569527.2016.1277430
dc.identifier.urihttps://hdl.handle.net/20.500.12587/7108
dc.identifier.volume36en_US
dc.identifier.wosWOS:000413604300003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofCutaneous And Ocular Toxicology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntimicrobial peptidesen_US
dc.subjectmethotrexateen_US
dc.subjectpsoriasisen_US
dc.titleThe investigation of antimicrobial peptides expression and its related interaction with methotrexate treatment in patients with psoriasis vulgarisen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
The investigation of antimicrobial peptides expression and its related interaction with methotrexate treatment in patients with psoriasis vulgaris.pdf
Boyut:
1.22 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu